Search Results 851-860 of 17040 for monoclonal antibody

  1. A Study of Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer - Mayo Clinic

    Monoclonal antibody(ies). At least 28 days since last dose of monoclonal antibody prior to registration. Immunotherapy. At least 28 days since last dose of ...

  2. Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients - Mayo Clinic

    ... antibodies) treatment, CPI-naïve hepatocellular carcinoma (HCC), and ... Chemotherapy, other monoclonal antibodies, antibody-drug conjugates, or ...

  3. Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease - Mayo Clinic

    Abnormal specific antibody response to immunization; ... Has received any lymphocyte depleting agents including anti-CD20 monoclonal antibodies, alemtuzumab, ATG ...

  4. Eating during cancer treatment: Tips to make food tastier - Mayo Clinic

    Monoclonal antibody drugs · Mort Crim and Cancer · Mouth sores caused by cancer treatment: How to cope · MRI · Muscle pain · Needle biopsy · Night sweats · No ...

  5. A Study Comparing CAR-T Therapy Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants with Relapsed and Lenalidomide-Refractory Multiple Myeloma - Mayo Clinic

    Serum monoclonal paraprotein (M-protein) level ≥ 1.0 gram per deciliter ... Monoclonal antibody treatment within 21 days. Cytotoxic therapy within 14 ...

  6. Multiple sclerosis - Symptoms and causes - Mayo Clinic

    Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis. https://www.uptodate.com/contents/search. Accessed June 19, 2024 ...

  7. Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) - Mayo Clinic

    Prior immunotherapy & monoclonal antibody therapy are acceptable. Subjects who received prior cytotoxic chemotherapy after incomplete resection of ...

  8. Pemigatinib to Treat Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations - Mayo Clinic

    ... monoclonal antibody, if eligible for this therapy;. Anti-EGFR (epidermal growth factor receptor) monoclonal antibody, if eligible for this therapy.

  9. Clinical Trials - Mayo Nephrology Collaborative Group - Mayo Clinic Research

    Assess the effectiveness of daratumumab SC in treating patients with monoclonal immunoglobulin deposits (PGNMID) by assessing improvement in proteinuria at 12 ...

  10. Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer - Mayo Clinic

    ... antibody Patients in Expansion Phase, Cohorts 2 and 3; Previously ... Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to baseline ...